2025
A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus
Peng X, Klingensmith G, Hsia D, Xie Y, Czerniak R, Tamborlane W, Shah A. A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus. Diabetes Therapy 2025, 1-19. PMID: 40032809, DOI: 10.1007/s13300-025-01700-3.Peer-Reviewed Original ResearchType 2 diabetes mellitusAlogliptin treatmentEfficacy endpointPediatric patientsAntihyperglycemic therapyOral dipeptidyl peptidase-4 inhibitorHbA1c levelsRandomized phase 3 studyDipeptidyl peptidase-4 inhibitorsSafety of alogliptinPlacebo-controlled trialPhase 3 studyBaseline to weekPeptidase-4 inhibitorsBody mass indexImprove glycemic controlDouble-blindPlacebo groupSecondary endpointsBackground metforminSchedule APharmacological therapyMass indexGlycosylated hemoglobinInsulin therapy
2012
The T1D Exchange Clinic Registry
Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA, Network F. The T1D Exchange Clinic Registry. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4383-4389. PMID: 22996145, DOI: 10.1210/jc.2012-1561.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic RegistryClinic registryAutoimmune type 1 diabetesFirst-degree family membersClinic-based registrySevere hypoglycemic eventsChronic diabetic complicationsType 1 diabetesContinuous glucose monitoringAssessment of associationsDiabetes historyDiabetic ketoacidosisEndocrinology centersPatient characteristicsRenal diseaseChart extractionT1D ExchangeGlycosylated hemoglobinHypoglycemic eventsDiabetic complicationsRetinopathy treatmentGeneral healthFamily historyMedical conditionsRegistry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply